ADMA Biologics, Inc. (ADMA) Earnings History
Annual and quarterly earnings data from 2007 to 2025
Loading earnings history...
ADMA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ADMA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 57.4% | 37.5% | 28.8% |
| 2024 | 51.5% | 32.6% | 46.4% |
| 2023 | 34.4% | 8.4% | -10.9% |
| 2022 | 22.9% | -25.5% | -42.8% |
| 2021 | 1.4% | -72.1% | -88.5% |
Download Data
Export ADMA earnings history in CSV or JSON format
Free sign-in required to download data
ADMA Biologics, Inc. (ADMA) Earnings Overview
As of May 8, 2026, ADMA Biologics, Inc. (ADMA) reported trailing twelve-month net income of $165M, reflecting -25.9% year-over-year growth. The company earned $0.69 per diluted share over the past four quarters, with a net profit margin of 28.8%.
Looking at the long-term picture, ADMA's historical earnings data spans multiple years. The company achieved its highest annual net income of $198M in fiscal 2024.
ADMA Biologics, Inc. maintains industry-leading profitability with a gross margin of 57.4%, operating margin of 37.5%, and net margin of 28.8%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including GRFS ($401M net income, 5.3% margin), BIO ($169M net income, 29.4% margin), PRPH (-$42M net income, -788.2% margin), ADMA has outperformed on profitability metrics. Compare ADMA vs GRFS →
ADMA Earnings vs Peers
Earnings metrics vs comparable public companies
ADMA Historical Earnings Data (2007–2025)
19 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $147M | -25.7% | $191M | $0.60 | 28.8% | 37.5% |
| 2024 | $198M | +800.0% | $139M | $0.81 | 46.4% | 32.6% |
| 2023 | -$28M | +57.2% | $22M | $-0.13 | -10.9% | 8.4% |
| 2022 | -$66M | +8.0% | -$39M | $-0.43 | -42.8% | -25.5% |
| 2021 | -$72M | +5.4% | -$58M | $-0.61 | -88.5% | -72.1% |
| 2020 | -$76M | -56.9% | -$65M | $-1.02 | -179.4% | -153.8% |
| 2019 | -$48M | +26.6% | -$41M | $-1.05 | -164.5% | -141.1% |
| 2018 | -$66M | -50.2% | -$60M | $-1.45 | -387.1% | -354.9% |
| 2017 | -$44M | -124.2% | -$39M | $-1.91 | -192.3% | -172.7% |
| 2016 | -$20M | -8.6% | -$17M | $-1.61 | -183.1% | -162.6% |
See ADMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADMA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ADMA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonADMA — Frequently Asked Questions
Quick answers to the most common questions about buying ADMA stock.
Is ADMA growing earnings?
ADMA EPS fell to $0.69, with earnings declining -25.9%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $165M.
What are ADMA's profit margins?
ADMA Biologics, Inc. net margin is +28.8%, with operating margin at +37.5%. Above-average margins indicate pricing power.
How consistent are ADMA's earnings?
ADMA earnings data spans 2007-2025. The declining earnings trend is -25.9% YoY. Historical data enables comparison across business cycles.